

Processing your request...
Dialog Index Results

Your select statement is 'S PAM(3N)CYS (30N)THIOESTER' in databases
ALLMEDPH.

☒ Select All

☒ Clear Selections

Begin Databases

New Search

Sort Results

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	1
<input type="checkbox"/> 440:	<u>Current Contents Search®</u>	1

There are 2 databases matching your statement 'S PAM(3N)CYS
(30N)THIOESTER'.

© 2003 The Dialog Corporation

Processing your request...
Dialog Index Results

Your select statement is 'S PALM?(15N)THIOESTER' in databases ALLMEDPH.

☒ Select All ☒ Clear Selections

<u>File</u>	<u>Database Name</u>	<u>Hits</u>
<input type="checkbox"/> 5:	<u>BIOSIS Previews® (1969-present)</u>	110
<input type="checkbox"/> 34:	<u>SciSearch® - a Cited Reference Science Database - 1990-</u>	89
<input type="checkbox"/> 35:	<u>Dissertation Abstracts Online</u>	12
<input type="checkbox"/> 50:	<u>CAB ABSTRACTS</u>	5
<input type="checkbox"/> 51:	<u>Food Science and Technology Abstracts</u>	2
<input type="checkbox"/> 65:	<u>Inside Conferences</u>	1
<input type="checkbox"/> 71:	<u>Elsevier Biobase</u>	57
<input type="checkbox"/> 73:	<u>EMBASE® (1974-present)</u>	119
<input type="checkbox"/> 88:	<u>Gale Group Business A.R.T.S. (SM)</u>	10
<input type="checkbox"/> 94:	<u>JICST-EPlus - Japanese Science & Technology</u>	1
<input type="checkbox"/> 98:	<u>General Science Abstracts/Fulltext</u>	11
<input type="checkbox"/> 103:	<u>Energy Science and Technology</u>	6
<input type="checkbox"/> 143:	<u>Wilson Biological & Agricultural Index</u>	5
<input type="checkbox"/> 144:	<u>PASCAL</u>	24
<input type="checkbox"/> 149:	<u>Gale Group Health & Wellness Database(SM)</u>	7
<input type="checkbox"/> 155:	<u>MEDLINE® (1966-present)</u>	114
<input type="checkbox"/> 156:	<u>TOXFILE</u>	17
<input type="checkbox"/> 159:	<u>CANCERLIT®</u>	20
<input type="checkbox"/> 162:	<u>CAB HEALTH</u>	2
<input type="checkbox"/> 172:	<u>EMBASE® Alert</u>	1
<input type="checkbox"/> 266:	<u>Federal Research in Progress (FEDRIP)</u>	1
<input type="checkbox"/> 285:	<u>BioBusiness®</u>	1
<input type="checkbox"/> 348:	<u>European Patents Fulltext</u>	29
<hr/>		
<input type="checkbox"/> 349:	<u>WIPO/PCT Patents Fulltext</u>	49

<input type="checkbox"/> 351:	<u>Derwent World Patents Index</u>	3
<input type="checkbox"/> 357:	<u>Derwent Biotechnology Resource</u>	1
<input type="checkbox"/> 370:	<u>Science</u>	1
<input type="checkbox"/> 377:	<u>Derwent Drug File (1983-present)</u>	3
<input type="checkbox"/> 399:	<u>CA SEARCH® - Chemical Abstracts® (1967-present)</u>	22
<input type="checkbox"/> 429:	<u>Adis Newsletters - Archive</u>	1
<input type="checkbox"/> 434:	<u>SciSearch® - a Cited Reference Science Database - 1974-1989</u>	2
<input type="checkbox"/> 440:	<u>Current Contents Search®</u>	94
<input type="checkbox"/> 441:	<u>ESPICOM Pharmaceutical & Medical Device News</u>	1
<input type="checkbox"/> 459:	<u>Proux Science Daily Essentials - Weekly</u>	1
<input type="checkbox"/> 484:	<u>Periodical Abstracts PlusText(TM)</u>	6
<input type="checkbox"/> 654:	<u>U.S. Patents Fulltext (1976-present)</u>	78

There are 36 databases matching your statement 'S PALM?(15N)THIOESTER'.

☒ Select All
 ☐ Clear Selections

© 2003 The Dialog Corporation

3/3,AB/4 (Item 1 from file: 34)

10028366 **Genuine Article#:** 475YB **Number of References:** 21

The nature of the bond between peptide and carrier molecule determines the immunogenicity of the construct

Author: Beekman NJCM; Schaaper WMM (REPRINT) ; Langeveld JPM; Boshuizen RS; Meloen RH

Corporate Source: Inst Anim Sci & Hlth ID Lelystad,Dept Mol Recognit,POB 65/NL-8200 AB Lelystad//Netherlands/ (REPRINT); Inst Anim Sci & Hlth ID Lelystad,Dept Mol Recognit,NL-8200 AB Lelystad//Netherlands/

Journal: JOURNAL OF PEPTIDE RESEARCH , 2001 , V 58 , N3 (SEP) , P 237-245

ISSN: 1397-002X **Publication date:** 20010900

Publisher: MUNKSGAARD INT PUBL LTD , 35 NORRE SOGADE, PO BOX 2148, DK-1016 COPENHAGEN, DENMARK

Language: English **Document Type:** ARTICLE

Abstract: The influence of the nature of the bond between a peptide and a (lipidic) carrier molecule on the immunogenicity of that construct was investigated. As types of bonds a thioester-, a disulfide-, an amide- and a thioether bond were investigated. As carrier molecules a peptide, an N-palmitoylated peptide or a C-16-hydrocarbon chain were used. The biostability of the bond between peptide and carrier molecule is thioether > amide > disulfide much greater than thioester. However, the immunogenic potency of the constructs used was found to be thioester > disulfide > amide > thioether. In conclusion, a construct with a bond between peptide and (lipidic) carrier molecule that is more susceptible to biological degradation is more immunogenic when used in a peptide-based vaccine than a bond that is less susceptible to biological degradation.

SciSearch(R) Cited Ref Sci (Dialog® File 34): (c) 2003 Inst for Sci Info. All rights reserved.

3/3,AB/7 (Item 1 from file: 88)

03628677 **Supplier Number:** 16942002

Protein lipidation in cell signalling.(Signal Transduction)

Casey, Patrick

Science , v268 , n5208 , p221(5)

April 14 , 1995

ISSN: 0036-8075

Language: English **Record Type:** Fulltext; Abstract

Word Count: 5125 **Line Count:** 00414

Author Abstract: The ability of cells to communicate with and respond to their external environment is critical for their continued existence. A universal feature of this communication is that the external signal must in some way penetrate the lipid bilayer surrounding the cell. In most cases of such signal acquisition, the signaling entity itself does not directly enter the cell but rather transmits its information to specific proteins present on the surface of the cell membrane. These proteins then communicate with additional proteins associated with the intracellular face of the membrane. Membrane localization and function of many of these proteins are dependent on their covalent modification by specific lipids, and it is the processes involved that form the focus of this article.

Gale Group Business A.R.T.S. (Dialog® File 88): (c) 2003 The Gale Group. All rights reserved.

3/3,AB/9 (Item 1 from file: 348)

01084994

Active hedgehog protein conjugate, process for its production and use

Title in German: Aktives Hedgehog-Protein-Konjugat, Verfahren zur Herstellung und Verwendung

Title in French: Conjuge de protein hedgehog active, procede pour sa production et utilisation

Patent Assignee: Roche Diagnostics GmbH, (205395), Sandhofer Strasse 116, 68305 Mannheim, (DE), (Applicant designated States: all)

Inventor: Esswein, Angelika, Birkenweg 4, 64572 Buettelborn, (DE)
Lang, Kurt, 10 Langoner Strasse, 82377 Penzberg, (DE)
Rueger, Petra, 13 Birkenstrasse, 82377 Penzberg, (DE)
Seytter, Tilmann, 14 Ahornstrasse, 82166 Lochham
(Grafelfing), (DE)

Legal Representative: Horner, Martin Grenville et al (45941), Cruikshank & Fairweather 19 Royal Exchange Square, Glasgow G1 3AE Scotland, (GB)

	Patent Number	Kind	Date
Patent	EP 953576	A1	991103 (Basic)
Application	EP 99108032		990423
Priority	EP 98107911		980430
	EP 98116733		980903

Designated States: AT; BE; CH; CY; DE; DK; ES; FI; FR; GB; GR; IE; IT; LI; LU; MC; NL; PT; SE

Extended Designated States: AL; LT; LV; MK; RO; SI

International Patent Class: C07K-014/47; C07K-019/00

Abstract EP 953576 A1

A hedgehog conjugate which is characterized in that it contains: a) a polypeptide composed of 10 to 30 hydrophobic amino acids and/or amino acids which form transmembrane helices and are positively charged, b) 1 to 4 aliphatic, saturated or unsaturated hydrocarbon residues with a chain length of 10 to 24 C atoms and with a hydrophobic action or c) a hydrophobic thio compound covalently bound to a hedgehog protein and which has a several-fold increased activity and is suitable as a pharmaceutical agent.

Abstract Word Count: 84 **Note:**

Figure number on first page: NONE

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS A	(English)	9944	485
SPEC A	(English)	9944	8647

Total word count	Document A	9132
Total word count	Document B	0
Total word count	Document A + B	9132

EUROPEAN PATENTS (Dialog® File 348): (c) 2003 European Patent Office. All rights reserved.

3/3,AB/10 (Item 2 from file: 348)

00503439

**METHODS AND COMPOSITIONS FOR THE IDENTIFICATION,
CHARACTERIZATION AND INHIBITION OF FARNESYL PROTEIN
TRANSFERASE**

**Title in German: METHODEN UND REAGENTIEN FUR DIE IDENTIFIKATION,
CHARAKTERISIERUNG UND INHIBITION VON
FARNESYL-PROTEIN-TRANSFERASE**

**Title in French: PROCEDES ET COMPOSITIONS SERVANT A
L'IDENTIFICATION, A LA CHARACTERISATION ET A L'INHIBITION DE LA
TRANSFERASE DE PROTEINE FARNESYLE**

Patent Assignee: THE UNIVERSITY OF TEXAS SYSTEM, (266347), 201 West
7th Street, Austin, Texas 78701-2981, (US), (Proprietor
designated states: all)

Inventor: BROWN, Michael, S., 5719 Redwood Lane, Dallas, TX 75209,
(US)
GOLDSTEIN, Joseph, L., 3831 Turtle Creek Boulevard, Apt.
22B, Dallas, TX 75219, (US)
REISS, Yuval, 15730 El-Estado Drive, Apt. 249, Dallas, TX
75248, (US)

Legal Representative: Dost, Wolfgang, Dr.rer.nat., Dipl.-Chem. et al (3049), Patent-
und Rechtsanwälte Bardehle . Pagenberg . Dost . Altenburg .
Geissler . Isenbruck Galileiplatz 1, 81679 Munchen, (DE)

	Patent Number	Kind	Date
Patent	EP 528820	A1	930303 (Basic)
	EP 528820	B1	961009
	EP 528820	B2	011219
	WO 9116340		911031
Application	EP 91907853		910418
	WO 91US2650		910418
Priority	US 510706		900418
	US 615715		901120

Designated States: AT; BE; CH; DE; DK; ES; FR; GB; GR; IT; LI; LU; NL; SE

International Patent C07K-007/06; C12N-009/10; C12N-015/54; C12Q-001/48;
Class: C07K-005/10; A61K-038/00

Note:

No A-document published by EPO

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200151	1217
CLAIMS B	(German)	200151	1172
CLAIMS B	(French)	200151	1391
SPEC B	(English)	200151	14773
Total word count	Document A		0
Total word count	Document B		18553
Total word count	Document A + B		18553

EUROPEAN PATENTS (Dialog® File 348): (c) 2003 European Patent Office. All rights reserved.

3/3,AB/11 (Item 3 from file: 348)

00450594

SURFACTANT COMPOSITIONS AND METHODS

Title in German: OBERFLACHENAKTIVE ZUSAMMENSETZUNGEN UND VERFAHREN

Title in French: COMPOSITIONS DE SURFACTANT ET METHODES Y RELATIVES

Patent Assignee: GENENTECH, INC., (210480), 460 Point San Bruno Boulevard, South San Francisco California 94080, (US), (Proprietor designated states: all)
Byk Gulden Lomborg Chemische Fabrik GmbH, (211754), Byk-Gulden-Str. 2, 78467 Konstanz, (DE), (Proprietor designated states: all)

Inventor: BENSON, Bradley, J., 170 Cresta Vista, San Francisco, CA 94127, (US)
FRENZ, John, H., P.O. Box 135, Brisbane, CA 94005, (US)
QUAN, Cynthia, P., 112 F Street, Redwood City, CA 94063, (US)
SHAK, Steven, 1133 Cambridge Road, Burlingame, CA 94010, (US)
SHIFFER, Kathleen, A., 1299 Arguello Boulevard 7, San Francisco, CA 94112, (US)
STULTS, John, T., 2445 Rollingwood Drive, San Bruno, CA 94066, (US)
VENUTI, Michael, C., 207 Montcalm Street, San Francisco, CA 94110, (US)

Legal Representative: Nicholls, Kathryn Margaret et al (60341), MEWBURN ELLIS York House 23 Kingsway, London WC2B 6HP, (GB)

	Patent Number	Kind	Date
Patent	EP 482097	A1	920429 (Basic)
	EP 482097	B1	010606
	WO 9100871		910124
Application	EP 90911834		900710
	WO 90US3856		900710
Priority	US 378688		890711

Designated States: AT; BE; CH; DE; DK; ES; FR; GB; IT; LI; NL; SE

Class:

Note:

No A-document published by EPO

Language (Publication,Procedural,Application): English; English; English

FULLTEXT AVAILABILITY:

Available Text	Language	Update	Word Count
CLAIMS B	(English)	200123	818
CLAIMS B	(German)	200123	678
CLAIMS B	(French)	200123	874
SPEC B	(English)	200123	5079

Total word count	Document A	0
Total word count	Document B	7449
Total word count	Document A + B	7449

EUROPEAN PATENTS (Dialog® File 348): (c) 2003 European Patent Office. All rights reserved.

3/3,AB/12 (Item 1 from file: 349)

00953484

CORE-GLYCOSYLATED HCV ENVELOPE PROTEINS

PROTEINES D'ENVELOPPE VHC GLYCOSYLEES AU CENTRE

Patent Applicant/Assignee:

INNOGENETICS N V, Intellectual Property Department, Technologiepark 6, B-9052 Ghent, BE, BE (Residence), BE (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

DEPLA Erik, Burgstraat 58, B-9070 Destelbergen, BE, BE (Residence), BE (Nationality), (Designated only for: US)

BOSMAN Alfons, Hulst 165, B-1745 Opwijk, BE, BE (Residence), BE (Nationality), (Designated only for: US)

DESCHAMPS Geert, Ganzeplass 31, B-9880 Aalter, BE, BE (Residence), BE (Nationality), (Designated only for: US)

SABLON Erwin, Robbroeklaan 1a, B-1785 Merchtem, BE, BE (Residence), BE (Nationality), (Designated only for: US)

SUCKOW Manfred, Urdenbacher Dorfstr. 35, 40593 Dusseldorf, DE, DE (Residence), DE (Nationality), (Designated only for: US)

SAMSON Isabelle, t' Ranke Riet 9, B-8501 Heule, BE, BE (Residence), BE (Nationality), (Designated only for: US)

VERHEYDEN Gert, Dellestraat 45, B-3220 Holsbeek, BE, BE (Residence), BE (Nationality), (Designated only for: US)

Legal Representative:

INNOGENETICS N V (commercial rep.), Intellectual Property Department, Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent, BE,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200286101 A2 20021031 (WO 0286101)

Application: WO 2002BE64 20020424 (PCT/ WO BE0200064)

Priority Application: EP 2001870088 20010424; US 2001305604 20010717

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 42839

English Abstract

The current invention relates to HCV envelope proteins or parts thereof which are the product of expression in eukaryotic cells. More particularly said HCV envelope proteins are characterized in that on average up to 80 % of their N-glycosylation sites are core-glycosylated. Of these N-glycosylated sites more than 70 % are glycosylated with an oligomannose containing 8 to 10 mannoses. Furthermore, the ratio of the oligomannoses with structure Man(7)-GlcNAc(2) over the oligomannose with structure Man(8)-GlcNAc(2) is less than or equal to 0.45. Less than 10 % of the oligomannoses is terminated with an alpha1,3 linked mannose. The HCV envelope proteins of the invention are particularly suited for diagnostic, prophylactic and therapeutic purposes. A suitable eukaryotic cell for production of the HCV envelope proteins of the invention is a Hansenula cell.

French Abstract

L'invention porte sur des proteines d'enveloppe VHC ou des parties d'enveloppe VHC qui resultent de l'expression des cellules eucaryotes. Plus precisement, ces proteines d'enveloppe VHC se caracterisent par le fait que, en moyenne, jusqu'a 80 % de leurs sites de N-glycosylation sont glycosyles au centre. Sur ces sites glycosyles au centre, plus de 70 % sont glycosyles avec une oligomannose possedant une structure definie par Man(8 a 10)-GlcNAc(2). Par ailleurs, le rapport oligomannose de structure Man(7)-GlcNAc(2) oligomannose de structure Man(8 a 10)-GlcNAc(2) est inferieur ou egal a 0,45. Moins de 10 % des oligomannoses se terminent par un mannose lie a α 1,3. Les proteines d'enveloppe VHC selon l'invention conviennent tout particulierement a des fins diagnostiques, prophylactiques et therapeutiques. Une cellule eucaryote utile a la fabrication de proteines d'enveloppe VHC est une celluleHansenula.

PCT FULLTEXT (Dialog® File 349): (c) 2003 WIPO/Univentio. All rights reserved.

3/3,AB/13 (Item 2 from file: 349)

00953375

**CONSTRUCTS AND METHODS FOR EXPRESSION OF RECOMBINANT HCV
ENVELOPE PROTEINS**

**CONSTRUCTIONS ET METHODES RELATIVES A L'EXPRESSION DE
PROTEINES D'ENVELOPPE RECOMBINANTES DU VHC**

Patent Applicant/Assignee:

INNOGENETICS N V, Technologiepark 6, B-9052 Ghent, BE, BE (Residence), BE (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

SABLON Erwin, Robbroeklaan 1a, B-1785 Merchtem, BE, BE (Residence), BE (Nationality), (Designated only for: US)

VAN BROEKHOVEN Annie, Mevr. Courtmansstraat 9, B-2600 Berchem, BE, BE (Residence), BE (Nationality), (Designated only for: US)

BOSMAN Alfons, Hulst 165, B-1745 Opwijk, BE, BE (Residence), BE (Nationality), (Designated only for: US)

DEPLA Erik, Burgstraat 58, B-9070 Destelbergen, BE, BE (Residence), BE (Nationality), (Designated only for: US)

DESCHAMPS Geert, Ganzeplass 31, B-9880 Aalter, BE, BE (Residence), BE (Nationality), (Designated only for: US)

Legal Representative:

INNOGENETICS N V (commercial rep.), Industriepark Zwijnaarde 7, Box 4, B-9052 Ghent, BE,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200285932 A2-A3 20021031 (WO 0285932)

Application: WO 2002BE62 20020424 (PCT/ WO BE0200062)

Priority Application: EP 2001870088 20010424; US 2001305604 20010717

Designated States: AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 36986

English Abstract

The current invention relates to vectors and methods for efficient expression of HCV envelope proteins in eukaryotic cells. More particularly said vectors comprise the coding sequence for an avian lysozyme signal peptide or a functional equivalent thereof joined to a HCV envelope protein or a part thereof. Said avian lysozyme signal peptide is efficiently removed when the protein comprising said avian lysozyme signal peptide joined to a HCV envelope protein or a part thereof is expressed in a eukaryotic cell. Suitable eukaryotic cells include yeast cells such as *Saccharomyces* or *Hansenula* cells.

French Abstract

La presente invention concerne des vecteurs et des methodes permettant une expression efficace de proteines d'enveloppe du VHC dans des cellules eucaryotes. Plus particulierement, lesdits vecteurs comprennent la sequence codante pour un peptide signal du lysozyme aviaire ou un equivalent fonctionnel dudit peptide, lie a une proteine d'enveloppe du VHC ou une partie de ladite proteine. Ce peptide signal du lysozyme aviaire est retire, de facon efficace, lorsque la proteine renfermant ledit peptide signal du lysozyme aviaire, lie a une proteine d'enveloppe du VHC ou une partie de cette derniere, est exprimee dans une cellule eucaryote. Parmi les cellules eucaryotes adaptees figurent des cellules de levure, telles que les cellules de *Saccharomyces* ou *Hansenula*.

3/3,AB/14 (Item 3 from file: 349)

00948789

POLYNUCLEOTIDE BINDING COMPLEXES COMPRISING STEROLS AND SAPONINS

COMPLEXES DE LIAISON DE POLYNUCLEOTIDES COMPRENANT DES STEROLS ET DES SAPONINES

Patent Applicant/Assignee:

PHAROMED A S, Skovbrynet 57, DK-2880 Bagsvaerd, DK, DK (Residence), DK (Nationality), (For all designated states except: US)

Patent Applicant/Inventor:

KIRKBY Nikolai Soren, Laessoesgade 14, 1.sal, DK-2200 Copenhagen N., DK, DK (Residence), DK (Nationality), (Designated only for: US)

DALSGAARD Kristian, Kalvehave Havnevej 22, DK-4771 Kalvehave, DK, DK (Residence), DK (Nationality), (Designated only for: US)

Legal Representative:

HOIBERG APS (agent), Store Kongensgade 59 B, DK-1264 Copenhagen K, DK,

Patent and Priority Information (Country, Number, Date):

Patent: WO 200280981 A2-A3 20021017 (WO 0280981)

Application: WO 2002DK229 20020404 (PCT/ WO DK0200229)

Priority Application: DK 2001560 20010404; US 2001308609 20010731

Designated States: AE AG AL AM AT (utility model) AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ (utility model) CZ DE (utility model) DE DK (utility model) DK DM DZ EC EE (utility model) EE ES FI (utility model) FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK (utility model) SK SL TJ TM TN TR TT TZ UA UG US UZ VN YU ZA ZM ZW

(EP) AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR

(OA) BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

(AP) GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW

(EA) AM AZ BY KG KZ MD RU TJ TM

Publication Language: English

Filing Language: English

Fulltext Word Count: 45213

English Abstract

The present invention pertains to complexes comprising sterols and saponins. The complexes are capable of binding a genetic determinant including a polynucleotide. The complexes may further comprise a lipophilic moiety, optionally a lipophilic moiety comprising a contacting group and/or a targeting ligand, and/or a saccharide moiety. The complexes may further comprise an immunogenic determinant and/or an antigenic determinant and/or a medicament and/or a diagnostic compound. The complexes may in even further embodiments be encapsulated by an encapsulation agent including a biodegradable microsphere. The present invention also pertains to pharmaceutical compositions and methods of treatment of an individual by therapy and/or surgery, methods of cosmetic treatment, and diagnostic methods practised on the human or animal body.

French Abstract

La presente invention concerne des complexes comprenant des sterols et des saponines. Les complexes de l'invention sont capables de lier un determinant genetique comprenant un polynucleotide. Les complexes precites peuvent en outre renfermer un fragment lipophile, facultativement un fragment lipophile comprenant un groupe de contact et/ou un ligand de ciblage, et/ou un fragment saccharide. Ces complexes peuvent aussi comprendre un determinant immunogene et/ou un determinant antigenique et/ou un medicament et/ou un compose diagnostique. Dans d'autres modes de realisation, les complexes de l'invention peuvent meme etre encapsules par un agent d'encapsulation comprenant une micosphere biodegradable. L'invention se rapporte enfin a des compositions pharmaceutiques et a des procedes permettant de traiter un individu par therapie et/ou chirurgie, a des procedes de traitement cosmetique, et a des procedes diagnostiques mis en oeuvre sur le corps humain ou animal.

PCT FULLTEXT (Dialog® File 349): (c) 2003 WIPO/Univentio. All rights reserved.

00324428

**NUCLEOTIDES SEQUENCES OF CANOLA AND SOYBEAN PALMITOYL-ACP
THIOESTERASE GENES AND THEIR USE IN THE REGULATION OF FATTY
ACID CONTENT OF THE OILS OF SOYBEAN AND CANOLA PLANTS
SEQUENCES NUCLEOTIDIQUES DES GENES DE PALMYTOYLE-ACP
THIOESTERASE DE SOJA ET DE CANOLA, ET LEUR UTILISATION POUR
MODULER LA TENEUR EN ACIDE GRAS DES HUILES DE SOJA ET DE
CANOLA**

Patent Applicant/Assignee:

E I DU PONT DE NEMOURS AND COMPANY,
HITZ William Dean,

Inventor(s):

HITZ William Dean,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9606936 A1 19960307

Application: WO 95US10627 19950825 (PCT/ WO US9510627)

Priority Application: US 94299044 19940831

Designated States: AM AU BB BG BR BY CA CN CZ EE FI GE HU IS JP KG KP KR
KZ LK LR LT LV MD MG MK MN MX NO NZ PL RO RU SG SI SK TJ TM TT UA US
UZ VN KE MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF
BJ CF CG CI CM GA GN ML MR NE SN TD TG

Publication Language: English

Fulltext Word Count: 27904

English Abstract

Nucleotide sequences have been isolated that encode a C16 specific ACP thioesterase. The instant nucleotide sequences are expressed in E. coli and plant tissue. These sequences have been used in the anti-sense inhibition of endogenous plant thioesterase and in the regulation of the acyl co-enzyme A pool for the reduction of saturated fatty acid content in vegetable oil.

French Abstract

Des sequences nucleotidiques codant une ACP (proteine transporteuse d'acyles) thioesterase specifique de C16 ont ete isolees. Les sequences nucleotidiques de la presente invention sont exprimees dans l'espece E. Coli et dans des tissus vegetaux, et ont ete utilisees dans l'inhibition antisens de la thioesterase endogene des plantes et dans la regulation de l'amas de coenzymes A d'acyle en vue de reduire la teneur en acides gras satures des huiles vegetales.

3/3,AB/28 (Item 17 from file: 349)

00198981

**METHODS AND COMPOSITIONS FOR THE IDENTIFICATION,
CHARACTERIZATION AND INHIBITION OF FARNESYL PROTEIN
TRANSFERASE**

**PROCEDES ET COMPOSITIONS SERVANT A L'IDENTIFICATION, A LA
CARACTERISATION ET A L'INHIBITION DE LA TRANSFERASE DE
PROTEINE FARNESYLE**

Patent Applicant/Assignee:

BOARD OF REGENTS THE UNIVERSITY OF TEXAS SYSTEM,
BROWN Michael S ,
GOLDSTEIN Joseph L,
REISS Yuval,

Inventor(s):

BROWN Michael S,
GOLDSTEIN Joseph L,
REISS Yuval,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9116340 A1 19911031

Application: WO 91US2650 19910418 (PCT/ WO US9102650)

Priority Application: US 90706 19900418; US 90715 19901120

Designated States: AT AT AU BB BE BF BG BJ BR CA CF CG CH CH CM DE DE DK
DK ES ES FI FR GA GB GB GR HU IT JP KP KR LK LU LU MC MG ML MR MW NL NL
NO PL RO SD SE SE SN SU TD TG US US

Publication Language: English

Fulltext Word Count: 18063

English Abstract

Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, enzymes involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight of between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme, as well as

procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21ras. Also disclosed is a family of compounds which act either as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme. The most potent inhibitors are ones in which phenylalanine occurs at the third position of a tetrapeptide whose amino terminus is cysteine.

French Abstract

Procedes et compositions pour l'identification, la caracterisation et l'inhibition de transferase de la proteine farnesyle, enzymes servant a la farnesylation de diverses proteines cellulaires, y compris des proteines ras associees au cancer telles que la p21ras. On presente une tranferase de proteine farnesyle qui a un poids moleculaire entre environ 70000 et environ 100000 d'apres la chromatographie par exclusion de gel. L'enzyme semble comprendre une ou deux sous-unites d'environ 50 kDa chacune. On decrit aussi des procedes d'analyse et de purification de l'enzyme, ainsi que des procedures d'utilisation de l'enzyme purifiee dans des protocoles de triage pour l'identification d'eventuels agents anticancereux qui inhibent l'enzyme et empechent ainsi l'expression de proteines telles que la p21ras. On presente enfin une famille de composees qui agissent soit comme de faux substrats pour l'enzyme ou comme inhibiteurs purs et peuvent par consequent etre employes pour l'inhibition de l'enzyme. Les inhibiteurs les plus puissants sont ceux dans lesquels la phenylalanine apparait a la troisieme position d'un tetrapeptide dont la terminaison amino est la cysteine.

PCT FULLTEXT (Dialog® File 349): (c) 2003 WIPO/Univentio. All rights reserved.

3/3,AB/29 (Item 18 from file: 349)

00183533

SURFACTANT COMPOSITIONS AND METHODS

COMPOSITIONS DE SURFACTANT ET METHODES Y RELATIVES

Patent Applicant/Assignee:

GENENTECH INC,

CALIFORNIA BIOTECHNOLOGY INC,

Inventor(s):

BENSON Bradley J,

FRENZ John H,

QUAN Cynthia P,

SHAK Steven,

SHIFFER Kathleen A,

STULTS John T,

VENUTI Michael C,

Patent and Priority Information (Country, Number, Date):

Patent: WO 9100871 A1 19910124

Application: WO 90US3856 19900710 (PCT/ WO US9003856)

Priority Application: US 89688 19890711

Designated States: AT AU BE CA CH DE DK ES FR GB IT JP LU NL SE

Publication Language: English

Fulltext Word Count: 6112

English Abstract

Stable lung surfactant compositions are provided, as well as methods for their preparation, modification, formulation, assay, and therapeutic use.

French Abstract

Compositions stables de surfactant pulmonaire, et methodes de preparation, modification, formulation, dosage, et utilisation therapeutique.

PCT FULLTEXT (Dialog® File 349): (c) 2003 WIPO/Univentio. All rights reserved.

3/3,AB/30 (Item 1 from file: 399)

121272875 CA: 121(23)272875r JOURNAL

The low affinity neurotrophin receptor, p75LNTR, is palmitoylated by thioester formation through cysteine 279

Author: Barker, Philip A.; Barbee, Garth; Misko, Thomas P.; Shooter, Eric M.

Location: Dep. Neurobiology, Stanford University School Medicine, Stanford, Can., 94305-5401

Journal: J. Biol. Chem.

Date: 1994

Volume: 269 **Number:** 48 **Pages:** 30645-50

CODEN: JBCHA3

ISSN: 0021-9258

Language: English

CA SEARCH(R) (Dialog® File 399): (c) 2003 American Chemical Society. All rights reserved.

3/3,AB/31 (Item 1 from file: 484)

01992313 (USE FORMAT 7 OR 9 FOR FULLTEXT)

New biological and clinical roles for the n-6 and n-3 fatty acids

Hansen, Harald S

Nutrition Reviews (INUT) , v52 n5 , p 162-167

May 1994

ISSN: 0029-6643 **Journal Code:** INUT

Document Type: Feature

Language: English **Record Type:** Fulltext; Abstract

Word Count: 3604 **Length:** Long (31+ col inches)

Abstract:

Four new findings of the biochemistry and biology of the essential n-3 fatty acids are discussed. The findings will augment current knowledge as to the role of the essential fatty acids in human health.

Periodical Abs Plustext (Dialog® File 484): (c) 2003 ProQuest. All rights reserved.

4826619

Utility

Methods of imaging and treatment with targeted compositions

Inventor:Unger, Evan C., Tucson, AZ

Wu, Yunqiu, Tucson, AZ

Assignee: Bristol-Myers Squibb Medical Imaging, Inc. (02), Princeton

Examiner: Travers, Russell (Art Unit: 167)

Assistant Examiner: Sharareh, Shahnam

Law Firm: Woodcock Washburn LLP

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6521211	A	20030218	US 99243640	19990201
CIP	Pending			US 98218660	19981221
CIP	Abandoned			US 96660032	19960601
CIP	Abandoned			US 96640464	19960501
CIP	Abandoned			US 95497684	19950601
Priority				US 99243640	19990201
				US 98218660	19981221
				US 96660032	19960601
				US 96640464	19960501
				US 95497684	19950601

Abstract:

Novel ultrasound methods comprising administering to a patient a targeted vesicle composition which comprises vesicles comprising a protein or polymer, encapsulating a gas, in combination with a targeting ligand, and scanning the patient using ultrasound. The scanning methods comprise exposing the patient to a first type of ultrasound energy, then interrogating the patient using a second type of ultrasound energy. The targeting ligand preferably targets tissues, cells or receptors including myocardial cells, endothelial cells, epithelial cells, cancer cells and the glycoprotein GPIIb/IIIa receptor. The methods may be used to detect a thrombus, enhancement of an old or echogenic thrombus, local concentrations of vesicles and vesicles targeted to tissues, cells or receptors.

US PAT.FULL. (Dialog® File 654): (c) FORMAT ONLY 2003 THE DIALOG CORP. All rights reserved.

4768141

Derwent Accession: 1999-602946

Utility

C/ Active hedgehog protein conjugate

Inventor: Esswein, Angelika, Buettelborn, DE

Lang, Kurt, Penzberg, DE

Rueger, Petra, Penzberg, DE

Seytter, Tilman, Graefelfing, DE

Assignee: Curis, Inc. (02), Cambridge, MA

Curis Inc (Code: 56622)

Examiner: Russel, Jeffrey E. (Art Unit: 163)

Law Firm: Ropes & Gray

Combined Principal Attorneys: Vincent, Matthew P.; Halstead, David

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6468978	A	20021022	US 99301199	19990420
Priority				EP 98107911	19980430
				EP 98116733	19980900

Abstract:

A hedgehog conjugate which is characterized in that it contains polypeptide composed of 10 to 30 hydrophobic amino acids and/or acids which form transmembrane helices and are positively charged to 4 aliphatic, saturated or unsaturated hydrocarbon residues with chain length of 10 to 24 C atoms and with a hydrophobic action or hydrophobic thio compound covalently bound to a hedgehog protein which has a several-fold increased activity and is suitable as a pharmaceutical agent.

Document type: C

US PAT.FULL. (Dialog® File 654): (c) FORMAT ONLY 2003 THE DIALOG CORP. All rights reserved.

4745421

Derwent Accession: 2003-110149

Utility

C/ Modified G protein subunits

Inventor: Kobilka, Brian, Palo Alto, CA

Lee, Tae Weon, Palo Alto, CA

Assignee: The Board of Trustees of the Leland Stanford Junior University
02), Palo Alto, CA

Stanford, Leland Jr University Trustees (Code: 49136)

Examiner: Horlick, Kenneth R. (Art Unit: 166)

Assistant Examiner: Strzelecka, Teresa

Law Firm: Bozicevic, Field & Francis LLP

Combined Principal Attorneys: Francis, Carol L.; Phinney, David D.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6448377	A	20020910	US 2000672239	2000092
Priority				US 2000672239	2000092

Abstract:

The present invention provides modified G protein [alpha]-subunits which are characterized by constitutive localization to the plasma membrane; enhanced binding to one or more of the normal receptor partners for that [alpha]-subunit; and efficient binding to and activation of G protein binding partners. The distribution of the modified [alpha]-subunits, which are "tethered" to the plasma membrane allows the regulation of receptor-G protein coupling, and thus G-protein signaling, in various biological systems.

Document type: C

US PAT.FULL. (Dialog® File 654): (c) FORMAT ONLY 2003 THE DIALOG CORP. All rights reserved.

D⁴

4741489

Derwent Accession: 1999-385356

Utility

CERTIFICATE OF CORRECTION

C/ Hydrophobically-modified hedgehog protein compositions and methods

Inventor: Pepinsky, R. Blake, Arlington, MA

Baker, Darren P., Hingham, MA

Wen, Dingyi, Waltham, MA

Williams, Kevin P., Natick, MA

Garber, Ellen A., Cambridge, MA

Taylor, Frederick R., Milton, MA

Galdes, Alphonse, Lexington, MA

Porter, Jeffrey, Cambridge, MA

Assignee: Curis, Inc. (02), Cambridge, MA

Biogen, Inc. (02), Cambridge, MA

Biogen Inc

Curis Inc (Code: 21695 56622)

Examiner: Spector, Lorraine (Art Unit: 166)

Assistant Examiner: O'Hara, Eileen B.

Law Firm: Ropes & Gray

Combined Principal Attorneys: Vincent, Matthew P.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 6444793	A	20020903	US 99325256	19990603
Continuation	Pending			WO 98US25676	19981203
Priority				US 99325256	19990603
				WO 98US25676	19981203

Abstract:

Hydrophobically-modified proteins and methods of making them are described. A hydrophobic moiety is attached to a surface amino acid residue of the protein. The hydrophobic moiety can be a lipid or a peptide. Alternatively, the protein can be derivatized by a wide range of chemical reactions that append a hydrophobic structure to the protein. The preferred protein is of mammalian origin and is selected from a group consisting of Sonic, Indian, and Desert hedgehog. The hydrophobic moiety is used as a convenient tether to which may be attached a molecule such as a cell membrane, liposome, or micelle.

Document type: C CERTIFICATE OF CORRECTION

4552446

Derwent Accession: 1996-160367

Reissue

C/ Nucleotide sequences of canola and soybean palmitoyl-ACP thioesterase genes and their use in the regulation of fatty acid composition of the oils of soybean and canola plants; ENCODING ACYL-ACYL CARRIER PROTEIN THIOESTERASE ENZYMES TO MODIFY PLANT LIPID COMPOSITION; CHIMERIC GENES AND SUITABLE REGULATORY SEQUENCES USED TO CREATE TRANSGENIC PLANTS WITH ALTERED LEVELS OF SATURATED FATTY ACIDS

Inventor:Hitz, William Dean, Wilmington, DE

Assignee: E. I. du Pont de Nemours and Company (02), Wilmington, DE
Du Pont de Nemours, E I & Co (Code: 25048)

Examiner: Nelson, Amy J. (Art Unit: 168)

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US RE37317	E	20010807	US 2000535828	20000328
Continuation	Abandoned			US 94299044	19940831
1st Reissue	US 5955650	A	19990921	US 97793410	19970228
PCT	WO 9606936		19960307	WO 95US10627	19950828
			371:19970224		
			102e:19970224		
Priority				US 2000535828	20000328
				US 97793410	19970228
				US 94299044	19940831

Abstract:

The preparation and use of nucleic acid fragments encoding acyl carrier protein thioesterase enzymes to modify plant lipid composition are disclosed. Also disclosed are chimeric genes incorporating such nucleic acid fragments and suitable regulatory sequences may be used to create transgenic plants with altered levels of saturated fatty acids.
Document type: C

4115573

Derwent Accession: 1999-189637

Utility

REASSIGNED

C/ Surfactant compositions and methods; EXPRESSING AND RECOVERING RECOMBINANTLY PRODUCED SURFACTANT PROTEIN-C, TREATING WITH ACTIVATED DERIVATIVE OF FATTY ACID, THUS FORMING FATTY ACID THIOESTER CYSTEINE RESIDUES; FOR STABLE, NONAGGREGATING THERAPY FOR PREMATURE

Inventor: Benson, Bradley J., Chapel Hill, NC

Frenz, John H., Brisbane, CA

Quan, Cynthia P., Redwood City, CA

Shak, Steven, Burlingame, CA

Shiffer, Kathleen A., Tiburon, CA

Venuti, Michael C., San Francisco, CA

Stults, John T., San Mateo, CA

Lesikar, David, Palo Alto, CA

Assignee: Byk Gulden Lomberg Chemische Fabrik GmbH (03), Constance, Byk-Gulden Lomberg Chemische Fabrik DE (Code: 12856)

Examiner: Jacobson, Dian C. (Art Unit: 162)

Assistant Examiner: Lou, Kawai

Law Firm: Morrison & Foerster LLP

Combined Principal Attorneys: Dylan, Ph.D., Tyler M.

	Publication Number	Kind	Date	Application Number	Filing Date
Main Patent	US 5876970	A	19990302	US 94278189	19940720
Continuation	Abandoned			US 9389411	19930709
Continuation	Abandoned			US 90550601	19900710
CIP	Abandoned			US 89378688	19890710
Priority				US 94278189	19940720
				US 9389411	19930709
				US 90550601	19900710
				US 89378688	19890710

Abstract:

Stable lung surfactant compositions are provided, as well as methods for their preparation, modification, formulation, assay, and therapeutic use.

Document type: C REASSIGNED

3306667

Derwent Accession: 1991-339750

Utility

C/ Isolated farnesyl protein transferase enzyme

Inventor: Brown, Michael S., Dallas, TX

Goldstein, Joseph L., Dallas, TX

Reiss, Yuval, Dallas, TX

Assignee: Board of Regents, The University of Texas System (02), Au:
Texas, University of System (Code: 83960)

Examiner: Brown, Johnnie R. (Art Unit: 183)

Assistant Examiner: Gitomer, Ralph

Law Firm: Arnold, White & Durkee

	Publication Number	Kind	Date	Application Number	Filing Date
	-----	--	-----	-----	-----
Main Patent	US 5141851	A	19920825	US 90615715	19901120
CIP	Abandoned			US 90510706	19900410
Priority				US 90615715	19901120
				US 90510706	19900410

Abstract:

Disclosed are methods and compositions for the identification, characterization and inhibition of farnesyl protein transferases, involved in the farnesylation of various cellular proteins, including cancer related ras proteins such as p21^{sup}ras. One farnesyl protein transferase which is disclosed herein exhibits a molecular weight between about 70,000 and about 100,000 upon gel exclusion chromatography. The enzyme appears to comprise one or two subunits of approximately 50 kDa each. Methods are disclosed for assay and purification of the enzyme as well as procedures for using the purified enzyme in screening protocols for the identification of possible anticancer agents which inhibit the enzyme and thereby prevent expression of proteins such as p21^{sup}ras. Also disclosed is a families of compounds which act as false substrates for the enzyme or as pure inhibitors and can therefore be employed for inhibition of the enzyme. The most potent inhibitors are ones in which phenylalanine occurs at the third position of a tetrapeptide whose amino terminus is cysteine.

Document type: C

US PAT.FULL. (Dialog® File 654): (c) FORMAT ONLY 2003 THE DIALOG CORP. All rights reserved.

 © 2003 The Dialog Corporation



'RD' - Duplicate detection is not supported for File 348.



'RD' - Duplicate detection is not supported for File 349.



'RD' - Duplicate detection is not supported for File 429.



'RD' - Duplicate detection is not supported for File 441.



'RD' - Duplicate detection is not supported for File 459.



'RD' - Duplicate detection is not supported for File 654.



'RD' - Records from unsupported files will be retained in the RD set.

Search History

Database Details

Set	Term Searched	Items	
S1	PALM?(15N)THIOESTER	901	Display
S2	S1 AND (GNRH OR LHRH OR HORMON?)	53	Display
S3	RD (unique items)	39	Display

Format

Free

Number of
Records

10

Show Database Details for:

5: BIOSIS Previews® (1969-present)

[Bluesheet](#)

[Rates](#)

[Fields](#)

[Formats](#)

[Sorts](#)

[Limits](#)

[Tags](#)

© 2003 The Dialog Corporation

3/3,AB/2 (Item 2 from file: 5)

08957703 Biosis No.: 199396109204

The G protein alpha-s subunit incorporates tritiated palmitic acid and mutation of cysteine-3 prevents this modification.

Author: Degtyarev Michael Y; Spiegel Allen M; Jone Teresa L Z(a)

Author Address: (a)MPB/ NIDDK, Build. 10, Room 8C-101, NIH, Bethesda, MD 20892**USA

Journal: Biochemistry 32 (32): p 8057-8061 1993

ISSN: 0006-2960

Document Type: Article

Record Type: Abstract

Language: English

Abstract: We investigated whether alpha-s could be acylated by palmitate by transfecting COS cells with the cDNA for the wild-type, long form of alpha-s and metabolically labeling with (3H)palmitate or (35S)methionine. Cells were separated into particulate and soluble fractions and immunoprecipitated with a specific peptide antibody. (3H)Palmitate was incorporated into both endogenous and transfected alpha-s. Inhibition of protein synthesis with cycloheximide did not block the radiolabeling of alpha-s with (3H)palmitate. Hydroxylamine treatment caused a release of the tritium radiolabel, demonstrating that the incorporation was through a thioester bond. The tritium radiolabel was base-labile and comigrated with (3H)palmitate on thin-layer chromatography. The third residue of the wild-type alpha-s was mutated from a cysteine to an alanine by site-directed mutagenesis. This mutant was expressed in COS cells and localized to the particulate fraction as determined by immunoprecipitation of the (35S)methionine-labeled cells. The cysteine-3 mutant did not undergo radiolabeling with (3H)palmitate, indicating that this residue is crucial for the modification.

1993

Biosis Previews(R) (Dialog® File 5): (c) 2003 BIOSIS. All rights reserved.

3/3,AB/3 (Item 3 from file: 5)

06224369 Biosis No.: 000086058551

**POST-TRANSLATIONAL PROTEIN MODIFICATION IN THE ENDOPLASMIC
RETICULUM DEMONSTRATION OF FATTY ACYLASE AND
DEOXYMANNOJIRIMYCIN-SENSITIVE ALPHA MANNOSIDASE ACTIVITIES**

Author: RIZZOLO L J; KORNFELD R

Author Address: DEP. ANAT. CELL BIOL., EMORY UNIV. SCH. MED., ATLANTA,
GA. 30322.

Journal: J BIOL CHEM 263 (19). 1988. 9520-9525. 1988

Full Journal Name: Journal of Biological Chemistry

CODEN: JBCHA

Record Type: Abstract

Language: ENGLISH

Abstract: We have previously described a hybrid protein, GHHA, that contains a fragment of the influenza hemagglutinin joined to the C terminus of a nearly complete rat growth hormone (Rizzolo, L. J., Finidori, J., Gonzalez, A., Arpin, M., Ivanov, I. E., Adesnik, M., and Sabatini, D. D. (1985) J. Cell Biol. 101, 1351-1362). GHHA was transported from the rough endoplasmic reticulum (ER) to a smooth cisterna, continuous with the rough ER, but proximal to the Golgi apparatus. We have now labeled GHHA with [3H]palmitate, demonstrating that fatty acylation can occur in the ER. As expected for a thioester linkage, the label was released from GHHA by hydroxylamine and identified as palmitic acid by thin-layer chromatography. In a second study, we analyzed the structure of the N-linked carbohydrate chain of GHHA. The N-linked oligosaccharides, all high-mannose type, were released by endoglycosidase H and size-fractionated by high pressure liquid chromatography. The predominant structures were Glc1Man8GlcNAc and Man8GlcNAc, indicating that only 2 or 3 glucose and 1 mannose residues were removed from the original Glc3Man9GlcNAc2. Determination of the structure by acetolysis fragmentation indicated that a single Man8GlcNAc isomer was formed by a deoxymannojirimycin-sensitive .alpha.-mannosidase. This contrasts with a previously characterized ER .alpha.-mannosidase (Bischoff, J., Liscum, L., and Kornfeld, R. (1986) J. Biol. Chem. 261, 4766-4774) that generates the same isomer, but is deoxymannojirimycin-resistant. These data suggest the possibility that different enzymes are partitioned within the ER.

1988

Biosis Previews(R) (Dialog® File 5): (c) 2003 BIOSIS. All rights reserved.

3/3,AB/5 (Item 2 from file: 34)

04319408 Genuine Article#: RW314 Number of References: 35

**BIOCHEMICAL-CHARACTERIZATION OF A PALMITOYL ACYLTRANSFERASE
ACTIVITY THAT PALMITOYLATES MYRISTOYLATED PROTEINS**

Author: BERTHIAUME L; RESH MD

Corporate Source: MEM SLOAN KETTERING CANC CTR,DEPT GENET & CELL
BIOL,1275 YORK AVE,BOX 143/NEW YORK//NY/10021; MEM SLOAN KETTERING
CANC CTR,DEPT GENET & CELL BIOL/NEW YORK//NY/10021

Journal: JOURNAL OF BIOLOGICAL CHEMISTRY , 1995 , V 270 , N38 (SEP 22) ,
P 22399-22405

ISSN: 0021-9258

Language: ENGLISH **Document Type:** ARTICLE

Abstract: Dynamic regulation of signal transduction by revers reversible palmitoylation-depalmitoylation cycles has been recently described, However, further understanding of fatty acylation reactions has been hampered by our lack of knowledge about the specific transferases and thio esterases involved. Here, we describe an assay for the palmitoyl acyltransferase (PAT) that palmitoylates "myrGlyCys" containing members of the Src family of protein tyrosine kinases (PTKs), Since N-myristoylation of Fyn PTK, a member of the Src family, has been shown to be a prerequisite for palmitoylation, a new single plasmid vector that allows overexpression of myristoylated Fyn substrate in Escherichia coli was developed, Purified myristoylated protein substrates were incubated with [I-125]iodopalmitoyl CoA, a palmitoyl CoA analog, in the presence of bovine brain lysates, Transfer of radiolabel to the Fyn substrate was detected by SDS-polyacrylamide gel electrophoresis and autoradiography. This assay was used to partially purify and characterize PAT activity from bovine brain. Here, we demonstrate that PAT is a membrane-bound enzyme, which palmitoylates myristoylated Fyn substrates containing a cysteine residue in position three. The PAT activity attached palmitate to Fyn proteins via a thioester Linkage and exhibited a fatty acyl CoA preference for long chain fatty acids, It is likely that palmitoylation of Fyn and other Src family members by PAT regulates PTK localization and signaling functions.

SciSearch(R) Cited Ref Sci (Dialog® File 34): (c) 2003 Inst for Sci Info. All rights reserved.
